Compare OBK & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | FTRE |
|---|---|---|
| Founded | 1912 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2023 |
| Metric | OBK | FTRE |
|---|---|---|
| Price | $50.79 | $17.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $46.67 | $14.06 |
| AVG Volume (30 Days) | 137.2K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $5.79 | $3.09 |
| P/E Ratio | $57.22 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $32.13 | $4.46 |
| 52 Week High | $52.90 | $18.67 |
| Indicator | OBK | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 62.82 |
| Support Level | $48.10 | $15.40 |
| Resistance Level | $52.90 | $18.13 |
| Average True Range (ATR) | 1.04 | 0.90 |
| MACD | -0.18 | -0.05 |
| Stochastic Oscillator | 26.99 | 80.00 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.